Higher dexamethasone clearance was associated with cumulative incidence of any (hematologic, CNS, and other) relapse
| Factors* . | Hazard ratio . | 95% CI . | P† . |
|---|---|---|---|
| Dexamethasone CL/F (L/h per m2) per 50-unit change‡ | 1.56 | 1.1-2.19 | .0104 |
| Anti–ASP antibody positive vs negative | 0.57 | 0.09-3.76 | .56 |
| ASP antibody timing§ | 0.74 | 0.23-2.36 | .61 |
| Older than 10 years vs 1-10 years | 0.61 | 0.23-1.59 | .31 |
| Initial leukocyte count ≥ 100 cells/mm3 vs < 100 cells/mm3 | 1.87 | 0.57-6.16 | .30 |
| Black vs white‖ | 2.84 | 1.13-7.1 | .0261 |
| Other vs white‖ | 1.22 | 0.33-4.42 | .76 |
| T-lineage vs B-lineage¶ | 1.63 | 0.67-4.0 | .28 |
| MRD 46 positive vs negative# | 1.31 | 0.48-3.62 | .60 |
| SR/HR vs LR | 5.99 | 1.80-19.97 | .0035 |
| Factors* . | Hazard ratio . | 95% CI . | P† . |
|---|---|---|---|
| Dexamethasone CL/F (L/h per m2) per 50-unit change‡ | 1.56 | 1.1-2.19 | .0104 |
| Anti–ASP antibody positive vs negative | 0.57 | 0.09-3.76 | .56 |
| ASP antibody timing§ | 0.74 | 0.23-2.36 | .61 |
| Older than 10 years vs 1-10 years | 0.61 | 0.23-1.59 | .31 |
| Initial leukocyte count ≥ 100 cells/mm3 vs < 100 cells/mm3 | 1.87 | 0.57-6.16 | .30 |
| Black vs white‖ | 2.84 | 1.13-7.1 | .0261 |
| Other vs white‖ | 1.22 | 0.33-4.42 | .76 |
| T-lineage vs B-lineage¶ | 1.63 | 0.67-4.0 | .28 |
| MRD 46 positive vs negative# | 1.31 | 0.48-3.62 | .60 |
| SR/HR vs LR | 5.99 | 1.80-19.97 | .0035 |
ASP indicates asparaginase; and MRD 46, minimal residual disease at the end of remission induction.
Prognostic features included in this model are known to be associated with treatment outcome in St Jude Total XV cohort by univariate analysis.9
P value from multivariate analysis using Fine and Gray regression model.18
Dexamethasone clearance is continuous variable, and the hazard ratio is calculated for every 50-unit change in clearance.
Timing when the patients first tested positive for anti–asparaginase antibody.
Genetically determined race as described.10
Acute lymphoblastic leukemia immunophenotype.
MRD positive is ≥ 0.01% (1 or more lymphoblasts among 104 mononuclear cells in the bone marrow) and MRD negative is < 0.01% lymphoblasts in the bone marrow sample.